Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.

Andreas E Kremer Marlyn J Mayo Gideon M Hirschfield Cynthia Levy Christopher L BowlusDavid E JonesJeff D Johnson Charles A McWherter Yun-Jung Choi

Published in: Hepatology (Baltimore, Md.) (2023)

Seladelpar decreased serum IL-31 and bile acids in patients with PBC. The reductions of IL-31 and bile acids correlated closely with each other and pruritus improvement, suggesting a mechanism to explain seladelpar's antipruritic effects.

Keyphrases